search
Back to results

Saccadic Eye Movements in Patients With Niemann-Pick Type C Disease

Primary Purpose

Niemann Pick Diseases

Status
Completed
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
OGT918
Sponsored by
National Eye Institute (NEI)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Niemann Pick Diseases focused on measuring Eye Movement, Niemann Pick C

Eligibility Criteria

12 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

INCLUSION CRITERIA: Patients with NPC disease confirmed by abnormal cholesterol esterification and abnormal filipin staining. Patients aged 12 and over. Body weight must not be less than 14 kg. Patients who can ingest a capsule. EXCLUSION CRITERIA: Patients younger than 18 who are unable to give informed assent and/or whose legal guardian is unable to provide informed consent. Patients aged 18 and over who cannot provide informed consent and/or whose legal guardian is unable to provide witnessed informed consent. Fertile patients who do not agree to use adequate contraception throughout the study and for three months after cessation of OGT 918 treatment. Patients who cannot tolerate the study procedures or who are unable to travel to the study center as required by this protocol. Patients currently undergoing therapy with other investigational agents or patients taking drugs or food supplements which may interfere with gastrointestinal absorption or motility. Patients suffering from clinically significant diarrhoea (greater than 3 liquid stools per day for greater than 7 days) without definable cause within 3 months of Screening Visit, or who have a history of significant gastrointestinal disorders. Patients with an intercurrent medical condition that would render them unsuitable for the study e.g. HIV, hepatitis infection. Patients who in the opinion of the investigator (for whatever reason) are thought to be unsuitable for the study.

Sites / Locations

  • National Institutes of Health Clinical Center, 9000 Rockville Pike
  • Columbia University
  • Oxford GlycoSciences Ltd.

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
April 19, 2006
Last Updated
June 30, 2017
Sponsor
National Eye Institute (NEI)
search

1. Study Identification

Unique Protocol Identification Number
NCT00316498
Brief Title
Saccadic Eye Movements in Patients With Niemann-Pick Type C Disease
Official Title
A Phase I/II Randomized, Controlled Study of OGT 918 in Adult and Juvenile Patients With Niemann Pick C Disease
Study Type
Interventional

2. Study Status

Record Verification Date
August 15, 2007
Overall Recruitment Status
Completed
Study Start Date
October 17, 2002 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
August 15, 2007 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
National Eye Institute (NEI)

4. Oversight

5. Study Description

Brief Summary
This study is done in conjunction with a trial, conducted at Columbia University College of Physicians and Surgeons in New York and the Royal Manchester Children's Hospital in England, to examine the effectiveness of a new drug called OGT 918 for treating Niemann-Pick Type C (NPC) disease. Patients with this genetic disorder do not transport lipids (fatty substances) in their cells, resulting in problems of the liver, spleen and brain. An early sign of NPC is a reduced ability to move the eyes rapidly up and down or from side to side. These voluntary eye movements are called saccades. Patients in the OGT 918 trial who participate in this sub-study will have their saccadic eye movements measured to see if improvement occurs with OGT 918 treatment. Patients with Niemann-Pick Type C disease 12 years of age and older who are enrolled in the OGT 918 trial described above may be eligible for this study. Participants will have both vertical (up and down) and horizontal (side to side) saccadic eye movements measured at two time points before starting treatment with OGT 918 and after 12 months of treatment. For the test, patients sit in a chair with their head positioned as for a regular eye examination (steadied by a chin cup and headrest) and follow with their eyes a series of lights or laser spots moving on a screen at a distance of 1 meter (3 feet). During the test, patients wear either special recording glasses, infrared goggles, or special contact lenses for measuring eye movements. A full eye evaluation lasts about 1 hour, and each eye is evaluated twice. The evaluations are separated in time by at least an hour, and possibly a day.
Detailed Description
None given, verified by PI.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Niemann Pick Diseases
Keywords
Eye Movement, Niemann Pick C

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Enrollment
30 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
OGT918

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
INCLUSION CRITERIA: Patients with NPC disease confirmed by abnormal cholesterol esterification and abnormal filipin staining. Patients aged 12 and over. Body weight must not be less than 14 kg. Patients who can ingest a capsule. EXCLUSION CRITERIA: Patients younger than 18 who are unable to give informed assent and/or whose legal guardian is unable to provide informed consent. Patients aged 18 and over who cannot provide informed consent and/or whose legal guardian is unable to provide witnessed informed consent. Fertile patients who do not agree to use adequate contraception throughout the study and for three months after cessation of OGT 918 treatment. Patients who cannot tolerate the study procedures or who are unable to travel to the study center as required by this protocol. Patients currently undergoing therapy with other investigational agents or patients taking drugs or food supplements which may interfere with gastrointestinal absorption or motility. Patients suffering from clinically significant diarrhoea (greater than 3 liquid stools per day for greater than 7 days) without definable cause within 3 months of Screening Visit, or who have a history of significant gastrointestinal disorders. Patients with an intercurrent medical condition that would render them unsuitable for the study e.g. HIV, hepatitis infection. Patients who in the opinion of the investigator (for whatever reason) are thought to be unsuitable for the study.
Facility Information:
Facility Name
National Institutes of Health Clinical Center, 9000 Rockville Pike
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20892
Country
United States
Facility Name
Columbia University
City
New York
State/Province
New York
ZIP/Postal Code
10032-3784
Country
United States
Facility Name
Oxford GlycoSciences Ltd.
City
Abingdon
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
9103204
Citation
Platt FM, Neises GR, Reinkensmeier G, Townsend MJ, Perry VH, Proia RL, Winchester B, Dwek RA, Butters TD. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science. 1997 Apr 18;276(5311):428-31. doi: 10.1126/science.276.5311.428.
Results Reference
background

Learn more about this trial

Saccadic Eye Movements in Patients With Niemann-Pick Type C Disease

We'll reach out to this number within 24 hrs